Skip to main content
Equibles
GANX logo

GANX · Gain Therapeutics, Inc.

Track GANX — free

Use GANX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GANX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.96 -0.04 (-2.00%)
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.”
View the 10-Q filed Aug 11, 2026
Market Cap
$87.51M
Shares
43.64M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.00 Open$2.01 Day$1.93–2.03 52W close$1.58–4.18 Avg vol 30d544K Short int3.2M · 7.4% float · 6.7d Short vol30% Last earningsMar 23, 2026 DataMar 2021–Aug 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.9 · calm Equity put/call 0.68
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg +9%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 16%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +8%
trailing
6-month return −24%
trailing
YTD return −38%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+23% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.36% of float · ▼ -10.4% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
49 holders — near 3-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Fair
Revenue growth −61%
Y/Y
EPS growth +31%
Y/Y
Free cash flow $-18.6M
Balance sheet $20.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −62%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
+9% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
16% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+23% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.36% of float · ▼ -10.4% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
49 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 16% Range high $4
vs 200-day avg -9% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Average decrease in GluSph in participants with elevated baseline levels after 90 days of treatm 81% Q1 2026 —
Participants enrolled in Phase 1b nine-month extension 16 Q1 2026 —
Participants who completed five months of dosing (Day 150) in Phase 1b nine-month extension 14 Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GANX
Gain Therapeutics, Inc.
this stock
$87.51M -37.9% -60.6% — 7.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.79B +20.8% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.30B +7.3% +20.8% 20.5 3.3%
ARGX
Argenx SE
 $63.81B +20.2% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
49
% held
20.1%
Net QoQ
+876.1K sh
Top holder
MARSHALL WACE, LLP
Held Float
View
Held by Funds
Fund positions
12
View
Short & Settlement
Short Interest Falling
Shares short
3.2M
Days to cover
6.7d
Change
-374.7K sh
View
Short Volume
Short vol %
30%
As of
Aug 24, 2026
Short Total
View
Fails to Deliver
FTD shares
75.5K
Value
$132.9K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
67.4%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$55.2K
Net income (FY)
$-20.2M
EPS diluted
$-0.61
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
14
View
Exempt Offerings
Offering
$10.0M
Filed
Jul 30, 2020
View
Earnings & Events
Earnings Calls
Last call
Mar 23, 2026
View

Performance

5D 20D 120D MTD YTD
GANX -2.0% +7.5% -24.0% +19.1% -37.9%
SPY -1.2% +3.3% +12.2% +2.2% +12.0%
vs SPY -0.8% +4.2% -36.2% +16.9% -49.9%
Key facts CIK 1819411 CUSIP 36269B105 13F (30d) 45 filings 45 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)